Table 2.
Baseline state anxiety | |||||||||
Low | Medium | High | |||||||
Mean VAS | Mean difference | p | 95% CI | Mean difference | p | 95% CI | Mean difference | p | 95% CI |
CBD-PLA | − 0.22 | > 0.99 | − 0.92, 0.48 | 0.28 | > 0.99 | − 0.20, 0.77 | 0.79 | 0.11 | 0.09, 1.49 |
THC/CBD-PLA | − 0.13 | > 0.99 | − 0.86, 0.60 | 0.84 | <0.01* | 0.34, 1.34 | 1.81 | <0.01* | 1.08, 2.55 |
THC-PLA | 1.53 | <0.01* | 0.88, 2.18 | 1.59 | <0.01* | 1.09, 2.09 | 1.65 | <0.01* | 0.99, 2.31 |
THC-THC/CBD | 1.66 | <0.01* | 0.99, 2.33 | 0.75 | 0.02* | 0.24, 1.26 | − 0.17 | > 0.99 | − 0.83, 0.50 |
Trait anxiety | |||||||||
Low | Medium | High | |||||||
Mean VAS | Mean difference | p | 95% CI | Mean difference | p | 95% CI | Mean difference | p | 95% CI |
CBD-PLA | − 0.34 | > 0.99 | − 1.03, 0.36 | 0.27 | > 0.99 | − 0.30, 0.84 | 0.88 | 0.06 | 0.17, 1.58 |
THC/CBD-PLA | 0.62 | 0.35 | − 0.09, 1.33 | 0.96 | <0.01* | 0.36, 1.56 | 1.30 | <0.01* | 0.50, 2.10 |
THC-PLA | 1.63 | <0.01* | 0.93, 2.32 | 1.66 | <0.01* | 1.07, 2.24 | 1.69 | <0.01* | 0.96, 2.42 |
THC-THC/CBD | 1.01 | 0.02* | 0.29, 1.72 | 0.70 | 0.10 | 0.89, 1.31 | 0.39 | > 0.99 | − 0.43, 1.20 |
VAS, visual analogue scale; CBD, cannabidiol; THC, delta-9-tetrahydrocannabinol; PLA, placebo
* indicates significant difference after Bonferroni correction